Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs

Summary

The goal of this clinical trial is to learn if Rebamipide effective in gastroprotection in patients with atrial fibrillation who are treated with Direct Oral Anticoagulants (DOACs). Another point is to compare efficacy of Rebamipide and of its combination with Pantoprazole with efficacy of Pantoprazole only. Participants will: Take one of three variants of treatments for up to 24 weeks. Visits to the clinic wil take place for screening and then every 8 weeks.

Timeline

Start

2022-01-11

Primary completion

2024-09-20

Completion

2024-09-20

Drugs

Indications